12 results about "Antisense RNA" patented technology

The present invention comprises a pharmaceutic composition comprising one or more hepatocyte nuclear factor four alpha antisense RNA 1 (HNF4A-AS1) targeting polynucleotides, wherein the one or more HNF4A-AS1 targeting polynucleotides is capable of repressing HNF4A-AS1 in a subject resulting in upregulation of HNF4A expression and / or increasing HNF4A P1:P2 isoform ratio in the subject. The present invention also provides a method of treatment of a HNF4A-associated disease in a subject comprising the step of administering a therapeutically effective amount of the pharmaceutical composition comprising one or more HNF4A- AS1 targeting polynucleotides of the present invention. The present invention also provides a method of downregulating HNF4A P2 isoform expression in a subject comprising the step of repressing HNF4A-AS1 in the subject.

The invention relates to the field of biological medicine, in particular to application of an IL7R inhibitor in preparation of a medicine for treating rosacea. The IL7R inhibitor comprises preparations for inhibiting the IL7R at the gene level and the protein level, the preparations for inhibiting the IL7R at the gene level comprise shRNA, siRNA, dsRNA, miRNA, cDNA and antisense RNA / DNA, and the preparations for inhibiting the IL7R at the protein level comprise small molecule compounds, peptides and antibodies. It is found for the first time that the targeted IL7R has a remarkable treatment effect on rosacea, the recurrence rate can be effectively reduced, and the skin lesion degree can be relieved. The discovery not only opens up a new direction for fundamental research of rosacea, but also provides a brand-new and breakthrough solution for clinical treatment of rosacea, and is expected to bring a more durable and stable treatment effect for patients.

This invention generally relates to a novel composition of RNA / mRNA medicines as well as vaccines produced by using replicase- and / or RNA-dependent RNA polymerase (RdRp)-mediated RNA cycling reaction (RCR). The present invention is useful for developing a variety of self-amplifying RNA / mRNA (samRNA) medicines and vaccines containing at least a replicase / RdRp-binding site in the 5′- or 3′-end, or both, of any desired RNA molecule, including but not limited to antisense RNA (aRNA), small interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA) / miRNA precursor, long non-coding RNA (lnRNA) and mRNA. These RNA molecules can be either in single-stranded or in double-stranded, or mixed, conformation. The samRNA so obtained is useful not only for producing RNA-based vaccines and / or medicines but also for generating the mRNA-associated proteins, peptides, and / or antibodies under a proper in-vitro or in-cell translation condition. The replicase / RdRp-binding sites used in samRNA are derived or modified from coronaviral (e.g. COVID-19) and / or hepatitis C viral (HCV) RNA-dependent RNA polymerases (RdRp) in either single-stranded or double-stranded compositions.

The invention belongs to the technical field of biological medicines, and particularly relates to a multi-target programmable dsRNA delivery platform and application thereof in pest control. The dsRNA delivery platform is a self-assembled micron-sized microsphere containing a target sequence, and the target sequence can be replaced by other pest and disease damage sequences; the target sequence comprises a positive-sense RNA (Ribonucleic Acid) with a complementary sequence as shown in SEQ ID No. 1 and an antisense RNA with a sequence as shown in SEQ ID No. 2. The positive-sense RNA has a complementary sequence as shown in SEQ ID No. 1. The delivery platform delivers the dsRNA in a targeted manner, the degradation rate of the dsRNA in a plant leaf surface environment can be remarkably reduced, mRNA of a corresponding targeted gene is specifically cut, and metabolic disorder of pests is caused, so that normal physiological activities of the pests are blocked, and the purpose of preventing and treating the pests is achieved.

Described herein are compositions, pharmaceutical compositions, kits, and methods of use relating to anti-Dio3os antisense RNA. In embodiments, antisense Dio3os compositions, kits, and methods are described to improve symptoms of osteoporosis, for example, osteoporosis induced by a disorder characterized by a thyroid hormone imbalance (i.e., hyperthyroidism or hypothyroidism). In embodiments, antisense Dio3os compositions, kits, and methods are described to improve sensitivity of cancer cells to anti-cancer therapeutics, for example, sensitivity of ER+ breast cancer or other breast cancer cells, thyroid cancer cells, prostate cancer cells, hepatocellular cancer cells, pancreatic cancer cells, and ovarian cancer cells that are sensitized or otherwise non-responsive to cancer therapeutics (for example, aromatase inhibitors or HDAC inhibitors). Combination therapies are also contemplated utilizing antisense RNA according to the present disclosure and other drugs, for example, thyroid and anti-cancer medications.

The invention relates to the technical field of agricultural biology, in particular to dsRNA of a pinus massoniana gene11 gene and application of the dsRNA, and the dsRNA is composed of a sense RNA chain shown in SEQ ID NO: 1 and an antisense RNA chain reversely complementary with the sense RNA chain. According to the dsRNA of the pine caterpillars gene11 gene and the preparation method and application thereof, the dsRNA is injected into pine caterpillars, target genes of the pine caterpillars are efficiently silenced, the death rate of the pine caterpillars can be increased, feeding behavior taxis is reduced, food digestion is affected, and finally the prevention and treatment effect is achieved; and a new effective way is provided for preventing and treating the pine caterpillars.

The present application relates to the field of biological medicine, and particularly relates to application of IL7R inhibitor in preparation of a drug for treating rosacea. The IL7R inhibitor includes preparations for inhibiting the IL7R at the gene level and the protein level, the preparation for inhibiting the IL7R at the gene level is shRNA, siRNA, dsRNA, miRNA, cDNA, antisense RNA / DNA, and the preparation for inhibiting the IL7R at the protein level is a small molecule compound, a peptide and an antibody. It is found for the first time that targeting IL7R has a significant therapeutic effect on rosacea, can effectively reduce the recurrence rate and reduce the degree of skin lesions. This finding not only opens up a new direction for the basic research of rosacea, but also provides a brand-new and breakthrough solution for the clinical treatment of rosacea, and is expected to bring more persistent and stable therapeutic effect for patients.

The application discloses a production technical process of gonad delayed development of large-mouth bass, and belongs to the technical field of aquatic animal biological breeding. The application creates new germplasm of large-mouth bass with significantly improved growth speed, significantly decreased gonad index and better muscle quality and flavor by parent cultivation, design of antisense RNA sequence and amplification, artificial insemination of the large-mouth bass after preparation of transfection reagent and introduction of the antisense RNA sequence of a key gender development gene, thereby providing technical support for promoting high-quality and sustainable development of the large-mouth bass industry.

The present invention provides a composition comprising one or more polynucleotides capable of upregulating expression of telomerase wherein telomerase consists of a protein component with reverse transcriptase activity encoded by telomerase reverse transcriptase (TERT) gene and a non-coding RNA encoded by telomerase RNA component (TERC) gene, In an embodiment, the one or more polynucleotides of the present invention upregulates the telomerase by downregulating antisense RNA that regulates telomerase gene. In an embodiment, the one or more polynucleotides comprises an siRNA or an shRNA. In an embodiment, one or more polynucleotides of the present invention is delivered by a nanoparticle such as an exosome that encapsulates the one or more polynucleotides. The present invention also provides a method of treatment of telomerase deficiency related diseases or disorders using any embodiment of the one or more polynucleotides of the present invention.

An HTT nucleic acid trans-splice molecule is described that includes a coding domain comprising one or more HTT exons, a splice site, and a binding domain that binds to a target intron of an HTT precursor mRNA. The HTT nucleic acid trans-splice molecules described herein may also be used in combination with, for example, an MSH3 binding domain aligned in series with an HTT binding domain, an MSH3 nucleic acid trans-splice molecule, an MSH3 splice modulator, an antisense oligonucleotide or antisense RNA for either of MSH3 or HTT, and an MSH3 or HTT microRNA (miRNA) and constructs encoding them. Also encompassed are compositions comprising the nucleic acid trans-splice molecules described herein, as well as compositions comprising a nucleic acid trans-splice molecule in combination with an additional therapeutic agent (e.g., an MSH3 nucleic acid trans-splice molecule, an MSH3 splice modulator, an antisense oligonucleotide or antisense RNA for any one of MSH3 or HTT). The nucleic acid trans-splicing molecules may be used alone or in combination with additional therapeutic agents in methods of treating Huntington's disease (HD). Also described herein are nucleic acid trans-splice molecules for use in the treatment of HD or in the preparation of medicaments for the treatment of HD, alone or in combination with additional therapeutic agents. Also encompassed herein are MSH3 nucleic acid trans-splice molecules, MSH3 splice modulators, and MSH3 miRNAs, as well as constructs encoding them, which can be used, alone or in combination and / or in combination with additional therapeutic agents, for the treatment of nucleotide repeat disorders (e.g., HD) or for the preparation of medicaments for the treatment of nucleotide repeat disorders (e.g., HD).

The present invention discloses a novel type of gene modulation technology for modulating target nucleic acid and / or protein levels in cells, tissues, organisms, and animals. This new technology provides compositions for use in gene modulation applications, including the prevention and treatment of human diseases. The compositions comprise short antisense RNA (asRNA) molecules having at least one deoxyribonucleotide monomer interspersed motif. The present invention further provides methods for using the compositions to modulate the expression or function of target genes, or for the treatment or prevention of diseases, as well as for biomedical research, disease diagnosis, and other biological applications.

The present invention provides a composition comprising one or more polynucleotides capable of upregulating expression of alpha- 1 anti-trypsin (Al AT). In an embodiment, the one or more polynucleotides of the present invention upregulates the expression of Al AT by downregulating antisense RNA that regulates the Al AT gene. In an embodiment, the one or more polynucleotides comprises an siRNA or an shRNA. In an embodiment, one or more polynucleotides of the present invention is delivered by a nanoparticle such as an exosome that encapsulates the one or more polynucleotides. The present invention also provides a method of treatment of Al AT deficiency related diseases or disorders using any embodiment of the one or more polynucleotides of the present invention.